Compare JD.Com Inc (JD) vs Moderna, Inc. (MRNA) Price & Performance

JD.com trades at $30.60, up 3.31% with strong recent earnings beats. The stock shows bullish technical signals with moving averages supporting upside, while RSI levels indicate potential overbought conditions. Fundamentally, revenue grew to $1.31 trillion in 2025, though net income margin compressed to 1.05%. Analyst consensus remains strongly bullish with a $39.50 price target, representing significant upside potential from current levels.

JD offers attractive valuation with P/S of 0.22 and P/E of 21.75, but faces risks from Chinese regulatory environment and ongoing margin pressure. The company maintains robust cash flow generation and shareholder returns through buybacks. Near-term catalyst includes Q2 2026 earnings release with expected EPS of $0.86.

Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.

The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.